Follow-up Study to Evaluate the Sustained Clinical Efficacy of Ragweed MATA MPL (Allergy Therapeutics) in Patients With Ragweed-Induced Seasonal Allergic Rhinitis Upon Re-Exposure to Ragweed Pollen in an Environmental Exposure Chamber (EEC) Model, Approximately One Year After Pre-Seasonal Treatment in 2005.

Trial Profile

Follow-up Study to Evaluate the Sustained Clinical Efficacy of Ragweed MATA MPL (Allergy Therapeutics) in Patients With Ragweed-Induced Seasonal Allergic Rhinitis Upon Re-Exposure to Ragweed Pollen in an Environmental Exposure Chamber (EEC) Model, Approximately One Year After Pre-Seasonal Treatment in 2005.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2009

At a glance

  • Drugs Ragweed allergy immunotherapy (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors Allergy Therapeutics
  • Most Recent Events

    • 11 Sep 2007 Status changed from in progress to completed.
    • 06 Jul 2007 Status changed from recruiting to in progress.
    • 12 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top